Acasti appoints Prashant Kohli as CEO; FDA allows Phase 3 safety study for GTX-104 to proceed

Grace Therapeutics, Inc.

Prashant Kohli appointed CEO effective April 4, 2023, succeeding Jan D'Alvise who mutually agreed to depart.
FDA Type C meeting response: concurred with 505(b)(2) pathway for GTX-104; Phase 3 safety study can proceed pending final protocol approval.
Phase 3 trial: 1:1 randomized vs oral nimodipine in aSAH patients at 25-30 US sites; primary endpoint is safety (hypotension adverse events).
First patient enrollment expected in H2 2023; if primary endpoint met, NDA filing under 505(b)(2) expected to follow.

item 5.02 item 7.01 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Jan D'Alvise

Director

GRCE · Grace Therapeutics, Inc.

Effective: 2023-04-04
Filed: April 5, 2023, 7:59 PM ET

Ms. D'Alvise will also be stepping down from the Company's board of directors.

Departed

Jan D'Alvise

Chief Executive Officer

GRCE · Grace Therapeutics, Inc.

Effective: 2023-04-04
Successor: Prashant Kohli
Filed: April 5, 2023, 7:59 PM ET

succeeding Jan D'Alvise, who has mutually agreed with the Company to depart.

Appointed

Prashant Kohli

Chief Executive Officer

GRCE · Grace Therapeutics, Inc.

Effective: 2023-04-04
Filed: April 5, 2023, 7:59 PM ET

On April 4, 2023, Acasti Pharma Inc. (the "Company") announced it has appointed Prashant Kohli as the Company's Chief Executive Officer, succeeding Jan D'Alvise, who has mutually agreed with the Company to depart.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Jan D'Alvise departed as Director at Grace Therapeutics, Inc..

Action: stepping down
Role: Director

Exact text from the filing

Ms. D'Alvise will also be stepping down from the Company's board of directors.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Jan D'Alvise departed as Chief Executive Officer at Grace Therapeutics, Inc..

Action: mutually agreed to depart
Role: Chief Executive Officer

Exact text from the filing

succeeding Jan D'Alvise, who has mutually agreed with the Company to depart.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Prashant Kohli was appointed as Chief Executive Officer at Grace Therapeutics, Inc..

Action: appointed
Role: Chief Executive Officer

Exact text from the filing

On April 4, 2023, Acasti Pharma Inc. (the "Company") announced it has appointed Prashant Kohli as the Company's Chief Executive Officer, succeeding Jan D'Alvise, who has mutually agreed with the Company to depart.

View on SEC.gov

Grace Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-011938

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.